Deprenyl: from chemical synthesis to neuroprotection.
(2006) In Journal of neural transmission. Supplementum 71. p.143-156- Abstract
- During the last decades (-)-deprenyl has become the golden standard of MAO-B inhibitors. It possesses dopamine potentiating and antioxidant properties; however, its effects cannot be explained solely by the enzyme inhibitory action. (-)-Deprenyl prevents the toxicity of certain selective neurotoxins and recently it was demonstrated to increase cell-cell adhesion as well. The complexity of its pharmacological effects reflects the action of both the parent compound and the active metabolites. (-)-Deprenyl and related propargylamines (DRPs) show neuroprotective features in a variety of in vitro and in vivo models that is dependent on the propargyl moiety. The main presumptive targets to date include glyceraldehyde-3-phosphate dehydrogenase,... (More)
- During the last decades (-)-deprenyl has become the golden standard of MAO-B inhibitors. It possesses dopamine potentiating and antioxidant properties; however, its effects cannot be explained solely by the enzyme inhibitory action. (-)-Deprenyl prevents the toxicity of certain selective neurotoxins and recently it was demonstrated to increase cell-cell adhesion as well. The complexity of its pharmacological effects reflects the action of both the parent compound and the active metabolites. (-)-Deprenyl and related propargylamines (DRPs) show neuroprotective features in a variety of in vitro and in vivo models that is dependent on the propargyl moiety. The main presumptive targets to date include glyceraldehyde-3-phosphate dehydrogenase, poly(ADP-ribose) polymerase, some kinase cascades, as well as pro- and antiapoptotic proteins, beside the inhibition of MAO-B. The antiapoptotic activity of DRPs converges upon the maintenance of mitochondrial integrity, due to the initiation of a comp (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1136388
- author
- Magyar, K. ; Palfi, M. ; Jenei, Veronica LU and Szoko, E.
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of neural transmission. Supplementum
- volume
- 71
- pages
- 143 - 156
- publisher
- Springer
- external identifiers
-
- scopus:34248550986
- ISSN
- 0303-6995
- language
- English
- LU publication?
- yes
- id
- 3eaed409-d170-44a0-9758-ff2b58577236 (old id 1136388)
- date added to LUP
- 2016-04-01 16:59:45
- date last changed
- 2022-01-28 23:34:00
@article{3eaed409-d170-44a0-9758-ff2b58577236,
abstract = {{During the last decades (-)-deprenyl has become the golden standard of MAO-B inhibitors. It possesses dopamine potentiating and antioxidant properties; however, its effects cannot be explained solely by the enzyme inhibitory action. (-)-Deprenyl prevents the toxicity of certain selective neurotoxins and recently it was demonstrated to increase cell-cell adhesion as well. The complexity of its pharmacological effects reflects the action of both the parent compound and the active metabolites. (-)-Deprenyl and related propargylamines (DRPs) show neuroprotective features in a variety of in vitro and in vivo models that is dependent on the propargyl moiety. The main presumptive targets to date include glyceraldehyde-3-phosphate dehydrogenase, poly(ADP-ribose) polymerase, some kinase cascades, as well as pro- and antiapoptotic proteins, beside the inhibition of MAO-B. The antiapoptotic activity of DRPs converges upon the maintenance of mitochondrial integrity, due to the initiation of a comp}},
author = {{Magyar, K. and Palfi, M. and Jenei, Veronica and Szoko, E.}},
issn = {{0303-6995}},
language = {{eng}},
pages = {{143--156}},
publisher = {{Springer}},
series = {{Journal of neural transmission. Supplementum}},
title = {{Deprenyl: from chemical synthesis to neuroprotection.}},
volume = {{71}},
year = {{2006}},
}